CRNXCrinetics Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Crinetics Pharmaceuticals, Inc. against iShares Biotechnology ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRNXThis | $8.8B#14 | — | 6.9x#6 | 1148.8x#13 | 640.7%#1 | -55.9%#14 | -6714.8%#14 | -36.3%#12 | — | — | 187.9%#1 | — |
| VRTX | $124.5B#4 | 29.1x#6 | 6.4x#4 | 10.4x#8 | 8.9%#8 | 838.1%#2 | 34.8%#2 | 20.4%#6 | 25.4%#3 | — | 4.6%#11 | — |
| GILD | $166.8B#3 | 18.3x#2 | 7.1x#7 | 5.7x#3 | 2.4%#12 | 1672.9%#1 | 34.0%#3 | 36.2%#3 | 21.6%#4 | — | 20.4%#8 | 2.4%#2 |
| AMGN | $212.1B#2 | 27.4x#5 | 23.1x#9 | 5.8x#4 | 10.0%#7 | 88.5%#5 | 24.7%#8 | 83.9%#1 | 15.3%#5 | — | 32.7%#5 | 2.4%#1 |
| REGN | — | 17.0x#1 | — | — | 1.0%#14 | 2.1%#7 | 24.9%#7 | 14.3%#7 | 9.6%#7 | — | 24.6%#7 | — |
| ALNY | $38.3B#7 | 123.9x#10 | 48.5x#11 | 10.3x#7 | 65.2%#3 | 212.8%#3 | 13.5%#9 | 39.8%#2 | — | — | -12.8%#13 | — |
| IQV | $40.7B#6 | 30.3x#7 | 6.5x#5 | 2.5x#1 | 5.9%#10 | -0.9%#10 | 13.4%#10 | 21.9%#5 | 9.1%#8 | — | 27.1%#6 | 1.4%#3 |
| ARGX | $53.9B#5 | — | — | — | — | — | — | — | — | — | 45.5%#4 | — |
| INSM | $22.6B#12 | — | 32.0x#10 | 37.2x#11 | 66.7%#2 | -39.7%#13 | -205.6%#13 | -181.1%#13 | -185.1%#11 | 4#3 | -0.9%#12 | — |
| MTD | $28.1B#11 | 32.6x#8 | — | 7.0x#5 | 4.0%#11 | 0.7%#9 | 27.8%#5 | — | 43.8%#1 | 5#2 | 9.8%#9 | — |
| NTRA | $36.1B#9 | — | 20.3x#8 | 15.6x#10 | 35.9%#5 | -9.3%#11 | -13.4%#12 | -11.7%#11 | -18.5%#10 | — | — | — |
| ONC | $477.2B#1 | 971.2x#11 | 100.3x#12 | 89.3x#12 | 40.2%#4 | 144.5%#4 | 8.4%#11 | 6.0%#9 | 32.7%#2 | 6#1 | 8.0%#10 | — |
| BIIB | $30.4B#10 | 22.2x#4 | 2.1x#1 | 3.1x#2 | 2.2%#13 | -20.8%#12 | 28.7%#4 | 8.7%#8 | 13.0%#6 | 4#3 | 61.2%#3 | — |
| UTHR | $22.2B#13 | 19.3x#3 | 3.8x#3 | 7.0x#6 | 10.6%#6 | 11.7%#6 | 46.9%#1 | 22.6%#4 | — | — | 76.0%#2 | — |
| WAT | $37.7B#8 | 48.9x#9 | 2.5x#2 | 11.9x#9 | 7.0%#9 | 0.8%#8 | 25.4%#6 | 4.2%#10 | 3.5%#9 | 4#3 | — | — |
Peer set: top holdings of IBB (iShares Biotechnology ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-07-29.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice